Rare Disease Report

Treatment Options for Castleman's Disease

JULY 07, 2014

In this exclusive interview, Dr. Nikhil Mushni of the Dana-Farber Cancer Institute talks about treatment options for Unicentric and Multicentric Castleman's disease.

Unicentric Castleman's disease can usually be treated by surgically removing the lymph node.

In Multicentic Castleman's disease, numerous treatments have been attempted but the only approved drug for Multicentic Castleman's disease - and the drug that seems to be effective - is the newly approved Sylvant (siltuximab). As Dr Munshi explains in this video, Sylvant neutralizes the high levels of IL-6 often observed in Castleman's disease.

More specifically, Sylvant is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Sylvant was not studied in patients with multicentric Castleman’s disease who are HIV positive or HHV-8 positive because Sylvant did not bind to virally produced IL-6 in a nonclinical study.

For more information about Castleman's disease, visit www.castlemans.org

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.